Bristol-Myers Squibb
BMY
BMY
1,763 hedge funds and large institutions have $62.7B invested in Bristol-Myers Squibb in 2018 Q4 according to their latest regulatory filings, with 208 funds opening new positions, 555 increasing their positions, 747 reducing their positions, and 155 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
2% less funds holding in top 10
Funds holding in top 10: 42 → 41 (-1)
16% less capital invested
Capital invested by funds: $74.8B → $62.7B (-$12.1B)
26% less repeat investments, than reductions
Existing positions increased: 555 | Existing positions reduced: 747
Holders
1,763
Holding in Top 10
41
Calls
$1.13B
Puts
$1.14B
Top Buyers
| 1 | +$500M | |
| 2 | +$254M | |
| 3 | +$211M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$196M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173M |
Top Sellers
| 1 | -$540M | |
| 2 | -$370M | |
| 3 | -$358M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$331M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$168M |